Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement

Dermatol Ther. 2022 Nov;35(11):e15818. doi: 10.1111/dth.15818. Epub 2022 Sep 22.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Biological Products* / adverse effects
  • Humans
  • Psoriasis* / drug therapy
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • tildrakizumab
  • Biological Products
  • Antibodies, Monoclonal, Humanized